Develops tegoprubart, an antibody therapy intended to prevent rejection in organ transplant recipients and treat amyotrophic lateral sclerosis in people living with the disease.
10-K for FY2025, filed Mar 19, 2026
No revenue reported yet.
10-K, filed Mar 3, 2017
10-Q for Q3 FY2026, filed Nov 12, 2026
−$3.9MView ↗
IgA nephropathy program
The older report said work on the IgA nephropathy program was deprioritized; the latest describes the program as discontinued.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 19, 2026In January 2023, the Company announced the deprioritization of its IgAN program. IgAN is the leading cause of chronic glomerulonephritis, a…View ↗
Our business strategy is to optimize the clinical and commercial value of tegoprubart and become a global biopharmaceutical company with a…View ↗
Loading...